Eikon Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines, primarily in the field of oncology. The company's foundational technology utilizes super-resolution microscopy, based on Nobel Prize-winning research, to measure the dynamic behavior of single-molecule proteins in living cells, enabling the discovery of novel therapeutics. Eikon's clinical pipeline includes its lead candidate, EIK1001, a TLR 7/8 dual-agonist currently in Phase 2/3 trials for advanced melanoma and non-small cell lung cancer. The pipeline also features PARP1 inhibitors (EIK1003 and EIK1004) and a WRN helicase inhibitor (EIK1005) targeting various solid tumors. Headquartered in California, the company operates as a single segment focused on drug discovery and clinical development, utilizing both in-house engineering and strategic in-licensing to build its portfolio.
